Tokyo, Japan – September 3, 2019 - MicroPort® CRM Japan Co. Ltd. is pleased to announce it has started direct sales operations today, with the first four implants of the KORA™ pacemakers that have been performed in several regions in Japan.
MicroPort® CRM Japan is a subsidiary of MicroPort® CRM, headquartered in greater Paris, France, and established in August 2018 with the objective to take over the direct distribution of CRM products in Japan from September 1, 2019.
MicroPort® CRM Japan will start introducing ENO™ in Japan, a new range of pacemakers with a volume of only 8cc. ENO™ pacemakers feature AutoMRI™ technology, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines. AutoMRI™ automatically switches in and out of MRI mode upon detection of the MR field, ensuring appropriate pacemaker operation during the scan and allowing patients to benefit from optimal pacing settings right up to and just after the scan.
"I am very proud of what the Japanese MicroPort® CRM team has achieved in just a few months to be ready to operate in Japan", said Noboru Shimizu, Vice President, Japan Country Manager. "Thanks to the skills of the team and the quality of our products, I am confident that we will be able to further strengthen the trust that physicians place in the MicroPort® CRM brand."
About MicroPort® CRM
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in greater Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort® Scientific Corporation.
For more information visit www.crm.microport.com